ZAG
0.047
56.7%
SRN
0.001
-50%
RAN
0.003
50%
GEN
0.012
-45.5%
CXL
0.675
45.2%
C7A
0.002
-33.3%
TDO
0.16
39.1%
RLG
0.003
-25%
1AD
0.004
33.3%
TMKDD
0.115
-23.3%
CPN
0.16
28%
VBS
0.195
-22%
SCP
0.125
27.6%
QXR
0.004
-20%
TGH
0.028
27.3%
RKB
0.004
-20%
MBK
0.019
26.7%
ENL
0.019
-17.4%
RMX
0.038
26.7%
AMS
0.03
-16.7%
ILA
0.525
23.5%
ALM
0.006
-14.3%
ATR
0.855
22.1%
SQX
0.15
-14.3%
VTX
0.265
20.5%
GCM
0.013
-13.3%
AKN
0.006
20%
GLA
0.013
-13.3%
AVL
0.012
20%
SHP
0.026
-13.3%
BLU
0.006
20%
DKM
0.165
-13.2%
VAR
0.006
20%
MRZ
0.3
-13%
SP8
0.013
18.2%
SCN
0.027
-12.9%
GDM
0.35
16.7%
ITM
0.055
-12.7%
ZEU
0.014
16.7%
CMO
0.021
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LTR Pharma (ASX:LTP) indicates first patients have received SPONTAN® under TGA Scheme

LTR Pharma (ASX:LTP) has announced that the first patients have received SPONTAN®, a nasal spray treatment for erectile dysfunction (ED), under the Therapeutic Goods Administration (TGA) Special Access Scheme. 

  • First patients receive SPONTAN® under the TGA Special Access Scheme
  • Demonstrates potential for SPONTAN® in an unmet fast-acting, on-demand erectile dysfunction treatment market
  • Internationally recognised Key Opinion Leader now actively engaged in prescribing SPONTAN®
    • Enables strategic market introduction and collection of real-world data
    • Platform to share experiences at international conferences and scientific publications.

LTR Pharma Chairman, Lee Rodne said: “The use of SPONTAN® under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN®.”